



# THYMIC HYPERPLASIA IN GRAVES' DISEASE -WAIT AND SEE, OR INTERVENE ?

# KAMATH C<sup>(1)</sup>, MCALEER B<sup>(2)</sup>, ADLAN MA<sup>(2)</sup>, PREMAWARDHANA LD<sup>(1,2)</sup>

Centre for Endocrine and Diabetes Sciences, University Hospital of Wales <sup>(1)</sup>, Heath Park, Cardiff, CF14 4XN Section of Endocrinology, YYF Hospital <sup>(2)</sup>, Ystrad Fawr Way, Caerphilly CF82 7EP, UK

# Introduction and Case Presentation

Thymic hyperplasia (TH) (figures 1, 2) occurs in autoimmune endocrine diseases such as Graves' disease (GD) and Addison's disease (AD) and is possibly related to its role in autoimmunity. Its true incidence is not known as thymic imaging is not undertaken routinely, and TH is usually diagnosed as a "thymic incidentaloma" in these conditions. We present 3 subjects with TH complicating GD and AD, who were managed expectantly, without intervention.

Subject 1 Subject 2 Subject 3 **Clinical presentation** 36 year old female – seen in chest clinic 37 year old female 47 year old female Osmotic symptoms ++, Weight loss - 5 stones Breathlessness, weight loss Pulse 120, BP 121/81 lying; 99/70 standing Referred to thoracic surgeons – CT abnormal

(C)

Referred to Thyroid clinic - thyrotoxic

Breathlessness + Chest pain Diagnosis - ? PE Weight loss, "Shakiness"

### **Investigations, Diagnosis and Progress**

- free T3 > 46.1; free T4 59.5; TSH < 0.01 (a) (b) Thyrotrophin Receptor Ab (TRAb) - 25.5
- Free T3 17; free T4 32; TSH < 0.02 (a) TRAb - 3.6 (after 7 months of treatment) (b)
- Free T3 6.7; free T4 18.7; (a) TSH < 0.02

- Corrected calcium 2.98; (d) PTH < 0.5(C)
- Short Synacthen test cortisol 305 (0min) and (e) 343 (30min); Adrenal antibodies – positive

Goitre, smooth, symmetrical, bruit +, No pigmentation

CT Thorax ABNORMAL (Figures 1a and 1b) (f)

GD and AD, presenting with hypercalcaemia

Clinically and biochemically stable on carbimazole, hydrocortisone and fludrocortisone

#### CT Thorax ABNORMAL (Figures 2a and (b) 2b) (C)

TRAb – 4.5 CTPA ABNORMAL (similar appearances to Fig 1a, 2a)

**GD** – thoracic surgery postponed

Stable on carbimazole

**GD - T3 toxicosis** 

Stable on carbimazole



**Benign thymic** hyperplasia (red solid arrows)

1. Arrowhead appearance 2. Sharp regular margins 3. No infiltration of organs 4. Isodense with muscles 4. No cysts / calcification

**BOX 1** 

### Significant regression of thymus \*\*

## Significant regression of thymus \*\*

# Discussion

- Thymic hyperplasia in GD, is benign in the vast majority CT scan appearances are helpful in 1) differentiating between benign and malignant enlargement (Box 1)
- There is evidence that the thymus regresses in the majority after treatment of GD (2)
- Interval scanning should be done several months after control of thyrotoxicosis (3)
- Two of our subjects had regression of their TH when GD was treated with thionamides (Figures (4)1b and 2b) – the third awaits interval scanning
- We recommend that TH in GD should be managed expectantly with interval scans after 6 months (5)of thionamide therapy, if initial scans confirm a benign morphology
- Major surgery may thus be avoided in these metabolically fragile subjects (6)



